Hyaluronic acid and other conservative treatment options for osteoarthritis of the ankle

Witteveen, Angélique G.H.; Hofstad, Cheriel J.; Kerkhoffs, Gino M. M. J.

doi:10.1002/14651858.cd010643.pub2

Cited by 56 publications

(43 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three meta-analyses 29 30 31 were excluded because they were performed to compare the efficacy and safety of HA with corticosteroids. Three studies, including primary studies in ankle/hip joints, were also excluded 32 33 34 .…”

Section: Resultsmentioning

confidence: 99%

Intra-articular Hyaluronic Acid in Treating Knee Osteoarthritis: a PRISMA-Compliant Systematic Review of Overlapping Meta-analysis

Xing

Wang

Liu

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Numerous meta-analyses have been conducted aiming to compare hyaluronic acid (HA) and placebo in treating knee osteoarthritis (OA). Nevertheless, the conclusions of these meta-analyses are not in consistency. The purpose of the present study was to perform a systematic review of overlapping meta-analyses investigating the efficacy and safety of HA for Knee OA and to provide treatment recommendations through the best evidence. A systematic review was conducted based on the PRISMA guidelines. The meta-analyses and/or systematic reviews that compared HA and placebo for knee OA were identified. AMSTAR instrument was used to evaluate the methodological quality of individual study. The information of heterogeneity within each variable was fetched for the individual studies. Which meta-analyses can provide best evidence was determined according to Jadad algorithm. Twelve meta-analyses met the eligibility requirements. The Jadad decision making tool suggests that the highest quality review should be selected. As a result, a high-quality Cochrane review was included. The present systematic review of overlapping meta-analyses demonstrates that HA is an effective intervention in treating knee OA without increased risk of adverse events. Therefore, the present conclusions may help decision makers interpret and choose among discordant meta-analyses.

show abstract

Section: Resultsmentioning

confidence: 99%

Intra-articular Hyaluronic Acid in Treating Knee Osteoarthritis: a PRISMA-Compliant Systematic Review of Overlapping Meta-analysis

Xing

Wang

Liu

et al. 2016

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Therefore, the concentration of HA is an indicator of the prognosis of patients with osteoarthritis. The efficacy of HA treatment in improving osteoarthritis symptoms has been widely studied and the clinical outcomes for patients with osteoarthritis are positive (19)(20)(21).…”

Section: Introductionmentioning

confidence: 99%

Clinical therapy of hyaluronic acid combined with platelet‑rich plasma for the treatment of knee osteoarthritis

Huang

et al. 2018

Exp Ther Med

View full text Add to dashboard Cite

Knee osteoarthritis is the most common degenerative disease of the joints caused by articular cartilage injury, degradation of the joint edge and subchondral bone hyperplasia. Various treatments are used to alleviate the symptoms of patients with knee osteoarthritis, including analgesics and intra-articular injections. Platelet-rich plasma (PRP) is an autologous and multifunctional platelet concentrate of the blood, which stimulates the cartilage healing process and improves the damage caused by articular disease. Hyaluronic acid (HA) is an effective treatment for patients with knee osteoarthritis. In the current study, the effectiveness of PRP and HA combination therapy administered via intra-articular injections for patients with knee osteoarthritis was analyzed. A total of 360 patients with knee osteoarthritis were randomized into four different treatment groups as follows: Double-blind treatment with PRP (2-14 ml); double-blind treatment with HA (0.1-0.3 mg); combination therapy of PRP and HA; and placebo groups. Following treatment, all patients were evaluated using the Western Ontario and McMaster Universities Arthritis Index (WOMAC) and Common Toxicity Criteria. The most common treatment-emergent adverse events were hypertension and proteinuria. The current study demonstrated that PRP and HA treatment significantly improved arthralgia, and PRP treatment was determined to be significantly more effective than HA treatment using the WOMAC pain score (P<0.05). PRP and HA combination treatment significantly improved arthralgia, reduced humoral and cellular immune responses and promoted angiogenesis, which improved the patients' histological parameters compared with PRP or HA treatment alone. These results suggested that PRP and HA combination treatment may be a potential treatment option for patients with knee osteoarthritis in the future.

show abstract

“…A 2015 Cochrane review (44) assessed the use of viscosupplementation for ankle OA. The authors reported uncertainty as to whether HA provides benefits versus placebo at 6 months, whether HA is superior to other treatments, which dosing schedule should be used, and which patients are likely to gain the most benefit.…”

Section: Discussionmentioning

confidence: 99%

Nonanimal Hyaluronic Acid for the Treatment of Ankle Osteoarthritis: AProspective, Single-Arm Cohort Study

Younger

Penner

Wing

et al. 2019

The Journal of Foot and Ankle Surgery

View full text Add to dashboard Cite

Ankle osteoarthritis (OA) can cause disabling symptoms, and some patients prefer to be treated with minimally invasive procedures. Nonanimal hyaluronic acid (NASHA) is a cross-linked hyaluronic acid product that has a prolonged intra-articular residence time. The authors report the first study of NASHA for the treatment of ankle OA. Thirtyseven patients with Kellgren-Lawrence grade II or III ankle OA received an intra-articular injection of NASHA (1 mL). Outcomes included visual analogue scale (VAS) scores for pain and disability. At baseline, the mean VAS pain score was 50.1 § 14.5 mm. During the 26-week follow-up period, the least squares (LS) mean change from baseline in the ankle OA VAS pain score was −20.5 mm (95% confidence interval [CI] ¡25.5 to ¡15.6 mm), an LS mean percentage reduction of 40.0% (95% CI 30.2% to 49.9%). The LS mean change from baseline in the VAS disability score during 26 weeks was ¡19.2 mm (95% CI ¡24.8 to ¡13.6 mm), a percentage reduction of 34% (95% CI 22.3% to 45.7%). Five participants experienced a total of 7 adverse events considered to be related to study treatment (injection site pain, n = 3; injection site joint pain, n = 3; plantar fasciitis, n = 1). This study shows promise for viscosupplementation with NASHA in the treatment of ankle OA. A single injection was associated with clinically meaningful reductions in pain and disability during a 26-week period and, in general, was well tolerated.

show abstract

Hyaluronic acid and other conservative treatment options for osteoarthritis of the ankle

Cited by 56 publications

References 74 publications

Intra-articular Hyaluronic Acid in Treating Knee Osteoarthritis: a PRISMA-Compliant Systematic Review of Overlapping Meta-analysis

Intra-articular Hyaluronic Acid in Treating Knee Osteoarthritis: a PRISMA-Compliant Systematic Review of Overlapping Meta-analysis

Clinical therapy of hyaluronic acid combined with platelet‑rich plasma for the treatment of knee osteoarthritis

Nonanimal Hyaluronic Acid for the Treatment of Ankle Osteoarthritis: AProspective, Single-Arm Cohort Study

Contact Info

Product

Resources

About